TEVA’s new data on thrice-weekly Copaxone are no big deal insofar as the comparator is placebo: http://finance.yahoo.com/news/teva-present-positive-data-glatiramer-060000096.html Teva will never run a head-to-head trial of thrice-weekly vs regular Copaxone. See #msg-77016146, #msg-63817727, and #msg-76644423 for background.